Despite correcting other hormone deficiencies, disruption of the oxytocin system and the potential benefits of the administration of exogenous oxytocin are yet to be assessed, and thus not considered in routine care for patients with craniopharyngioma. The gene discussed is OXT; the disease is craniopharyngioma.